Stay informed with the latest litigation news. Explore now

IP Verse

Ucb competitive analysis

Latest publications and patents of Ucb New

Explore the latest publications and patents granted to Ucb, showcasing their recent innovations and technological advancements.

Last updated on: Sep 9, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Ucb

EP3630946
Mar 27, 2024Cell Culture MethodsGranted And Under Opposition
EP2301961
Dec 13, 2023Sclerostin EpitopesPatent Maintained As Amended
EP3717631
Aug 30, 2023Cell Culture MethodsGranted And Under Opposition
EP3145504
Jul 26, 2023Transdermal Delivery System Including An Interface MediatorGranted And Under Opposition
EP2869844
Jun 21, 2023Treatment For Bone DiseasesPatent Maintained As Amended
EP3311168
May 10, 2023Novel Tnf Structure For Use In TherapyGranted And Under Opposition
EP2645997
Aug 10, 2022Once Daily Formulation Of LacosamideRevoked
EP2345668
Sep 22, 2021Sclerostin EpitopesGranted And Under Opposition
EP3670528
Sep 8, 2021Sclerostin Binding AgentsGranted And Under Opposition
EP2992891
Aug 5, 2020Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant EffectGranted And Under Opposition

Latest oppositions filed by Ucb

Explore patent oppositions filed by Ucb against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP2784084
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHApr 23, 2020
EP2531218
Immunoglobulin PreparationCSL BEHRINGSep 11, 2019
EP2282758
Antibodies And Vaccines For Use In Therapeutic And Diagnostic Methods For Alpha-Synuclein-Related DisordersBIOARCTICAug 21, 2019
EP2144613
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABDec 21, 2018
EP2606142
Method For Inactivating Proteases By Ph Change In A Liquid Obtained From A Cell CultureBOEHRINGER INGELHEIMNov 28, 2018
EP2586788
Prevention Of Disulfide Bond Reduction During Recombinant Production Of PolypeptidesGENENTECHAug 29, 2018
EP2794652
Rapid Method For Cloning And Expression Of Cognate Antibody Variable Region Gene SegmentsF HOFFMANN LA ROCHEAug 15, 2018

Latest patents of Ucb opposed by its competitors

Explore Ucb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3630946
Mar 27, 2024Cell Culture Methods4
EP2301961
Dec 13, 2023Sclerostin Epitopes1
EP3717631
Aug 30, 2023Cell Culture Methods2
EP3145504
Jul 26, 2023Transdermal Delivery System Including An Interface Mediator1
EP2869844
Jun 21, 2023Treatment For Bone Diseases1
EP3311168
May 10, 2023Novel Tnf Structure For Use In Therapy1
EP2645997
Aug 10, 2022Once Daily Formulation Of Lacosamide1
EP2345668
Sep 22, 2021Sclerostin Epitopes1
EP3670528
Sep 8, 2021Sclerostin Binding Agents1
EP2992891
Aug 5, 2020Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect1

Latest PTAB cases involving Ucb New

Discover the latest PTAB cases involving Ucb, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ucb

IPR2019-01481Aug 12, 2019UCBNOVIMMUNETerminated-Settled
IPR2019-01480Aug 12, 2019UCBNOVIMMUNETerminated-Settled
PGR2019-00044Apr 1, 2019UCBGENENTECHTerminated
IPR2019-00400Dec 13, 2018APOTEXUCB BIOPHARMAFinal Written Decision
IPR2016-01665Aug 22, 2016AMERIGEN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01596Aug 22, 2016ALEMBIC PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01636Aug 18, 2016TORRENT PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00517Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00516Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00514Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision

Top competitors of Ucb

Top competitors of Ucb based on patent oppositions.